Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)
Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%
Castle Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Castle Biosciences's profit margin for the twelve months ending Sep 30, 2026 was -6.1%. For fiscal 2025 it was -7.0%, against 5.5% the year before. The highest annual figure on record is 10.2% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -7.0% | −12.5 |
| FY2024 | Dec 31, 2024 | 5.5% | +31.6 |
| FY2023 | Dec 31, 2023 | -26.1% | +22.8 |
| FY2022 | Dec 31, 2022 | -49.0% | −15.7 |
| FY2021 | Dec 31, 2021 | -33.3% | −16.8 |
| FY2020 | Dec 31, 2020 | -16.4% | −26.6 |
| FY2019 | Dec 31, 2019 | 10.2% | +38.1 |
| FY2018 | Dec 31, 2018 | -27.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -4.0% | −3.4 |
| Q2 FY2026 | Jun 30, 2026 | -2.0% | −7.2 |
| Q1 FY2026 | Mar 31, 2026 | -17.4% | +12.0 |
| Q4 FY2025 | Dec 31, 2025 | -2.7% | −13.8 |
| Q3 FY2025 | Sep 30, 2025 | -0.6% | −3.2 |
| Q2 FY2025 | Jun 30, 2025 | 5.2% | −5.0 |
| Q1 FY2025 | Mar 31, 2025 | -29.4% | −25.9 |
| Q4 FY2024 | Dec 31, 2024 | 11.1% | +15.0 |
| Q3 FY2024 | Sep 30, 2024 | 2.6% | +13.9 |
| Q2 FY2024 | Jun 30, 2024 | 10.3% | +47.7 |
| Q1 FY2024 | Mar 31, 2024 | -3.5% | +66.0 |
| Q4 FY2023 | Dec 31, 2023 | -3.9% | +49.9 |
| Q3 FY2023 | Sep 30, 2023 | -11.2% | +43.5 |
| Q2 FY2023 | Jun 30, 2023 | -37.5% | −32.7 |
| Q1 FY2023 | Mar 31, 2023 | -69.5% | +22.2 |
| Q4 FY2022 | Dec 31, 2022 | -53.8% | −28.1 |
| Q3 FY2022 | Sep 30, 2022 | -54.7% | −4.5 |
| Q2 FY2022 | Jun 30, 2022 | -4.7% | +33.9 |
| Q1 FY2022 | Mar 31, 2022 | -91.7% | −72.9 |
| Q4 FY2021 | Dec 31, 2021 | -25.7% | +2.6 |
| Q3 FY2021 | Sep 30, 2021 | -50.2% | −20.1 |
| Q2 FY2021 | Jun 30, 2021 | -38.6% | −27.8 |
| Q1 FY2021 | Mar 31, 2021 | -18.8% | −22.0 |
| Q4 FY2020 | Dec 31, 2020 | -28.3% | −39.9 |
| Q3 FY2020 | Sep 30, 2020 | -30.2% | −69.7 |
| Q2 FY2020 | Jun 30, 2020 | -10.8% | +1.0 |
| Q1 FY2020 | Mar 31, 2020 | 3.3% | +18.9 |
| Q4 FY2019 | Dec 31, 2019 | 11.7% | −22.2 |
| Q3 FY2019 | Sep 30, 2019 | 39.6% | +132.5 |
| Q2 FY2019 | Jun 30, 2019 | -11.8% | +67.5 |
| Q1 FY2019 | Mar 31, 2019 | -15.6% | +83.6 |
| Q4 FY2018 | Dec 31, 2018 | 33.8% | – |
| Q3 FY2018 | Sep 30, 2018 | -92.9% | – |
| Q2 FY2018 | Jun 30, 2018 | -79.3% | – |
| Q1 FY2018 | Mar 31, 2018 | -99.2% | – |
See a number that looks wrong?